Avadel Pharmaceuticals PLC (AVDL)

8.08 +0.12  +1.51% NASDAQ May 29, 20:00 Delayed 2m USD

Avadel Pharmaceuticals Income Statement (Quarterly)

Export Data

March 2020 - December 2017

Previous Periods

Income (Quarterly) 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09 2018-06 2018-03 2017-12
Operating Revenue Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Revenue 12.24M 11.00M 14.23M 17.55M 16.44M 20.92M 19.83M 29.23M 33.29M 34.75M
Cost of Goods Sold Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Gross Profit 9.786M 8.581M 11.41M 13.93M 13.17M 16.63M 16.71M 25.72M 26.70M 30.70M
SG&A Expense 7.913M 7.663M 5.316M 6.758M 10.45M 23.20M 24.83M 27.84M 24.49M 23.06M
Research and Development Expense 5.53M 7.757M 7.539M 10.29M 7.329M 6.086M 11.40M 11.89M 9.951M 11.32M
Amortization Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Special Income and Charges Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Interest Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Operating Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Operating Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Operating Interest Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Non-Operating Interest Income Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Income and Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Pre-Tax Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Provision for Income Taxes Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Extraordinary Items, Income Statement Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Income -0.865M -2.739M -8.864M -8.605M -13.02M -63.86M -15.77M -3.438M -12.24M -8.245M
Normalized Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EBITDA Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Reconciled Depreciation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EBIT Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Basic EPS (Quarterly) 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09 2018-06 2018-03 2017-12
EPS Basic from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Extraordinaries Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Normalized Basic EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Diluted EPS (Quarterly) 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09 2018-06 2018-03 2017-12
EPS Diluted from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Extraordinaries Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Normalized Diluted EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted -0.02 -0.07 -0.24 -0.23 -0.35 -1.71 -0.43 -0.09 -0.32 -0.24
Shares Data (Quarterly) 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09 2018-06 2018-03 2017-12
Average Basic Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Average Diluted Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
SEC Filing Links 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09 2018-06 2018-03 2017-12
As Originally Reported AOR AOR AOR AOR AOR AOR AOR AOR AOR AOR
Restated Restated Restated Restated Restated Restated Restated

March 2020 - December 2017

Previous Periods

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.